Carcinogenesis, Vol. 21, No. 4, 563-565,
April 2000
© 2000 Oxford University Press
Cancer Biology |
High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis
INSERM EPI 9906, Faculté de Médecine et de Pharmacie, 22 Boulevard de Gambetta, 76183 Rouen and IFRMP, 76821 Mont-Saint-Aignan Cedex and
1 Centre de Dépistage et de Traitement des Tumeurs Digestives, CHU de Rouen, 76031 Rouen, France
Somatic mutations of the tumor suppressor gene p53 have been frequently detected in esophagal cancers, but their biological significance remains to be established. The tumor suppressor activity of p53 results in part from its ability to transactivate genes involved in the cell cycle and apoptosis, such as p21, bax and PIG3, and some p53 mutations may have a differential effect on the transactivation of these target genes. We developed yeast strains in which the activation by wild-type p53 of reporter plasmids containing p53 binding sites present within these target genes induces a change in the color of the colonies (red/white). Using these strains, we analyzed 56 esophageal cancers from patients residing in Normandy, France, a high incidence geographic area. Forty-seven tumors (84%), scored as mutant with the p21, bax and PIG3 reporter strains and in most of the cases (76%), the percentage of red colonies suggested that both p53 alleles were inactivated. Sequencing analysis allowed the identification of a p53 mutation in each positive sample, and the spectrum of mutations was in agreement with the etiological role of tobacco and alcohol. These results confirm the high frequency of biallelic p53 mutations in esophageal carcinoma and strongly suggest that their biological consequence is the complete alteration of the transactivation of genes involved in the cell cycle and apoptosis, which indicates that p53 alteration is a key event in esophagus carcinogenesis.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. R. Dearth, H. Qian, T. Wang, T. E. Baroni, J. Zeng, S. W. Chen, S. Y. Yi, and R. K. Brachmann Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers Carcinogenesis, February 1, 2007; 28(2): 289 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Breton, F. Sichel, A. Abbas, J. Marnay, D. Arsene, and M. Lechevrel Simultaneous use of DGGE and DHPLC to screen TP53 mutations in cancers of the esophagus and cardia from a European high incidence area (Lower Normandy, France) Mutagenesis, May 1, 2003; 18(3): 299 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Shirai, T. Tsukamoto, M. Yamamoto, T. Iidaka, H. Sakai, T. Yanai, T. Masegi, L. A. Donehower, and M. Tatematsu Elevated susceptibility of the p53 knockout mouse esophagus to methyl-N-amylnitrosamine carcinogenesis Carcinogenesis, September 1, 2002; 23(9): 1541 - 1547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Noori and S.-M. Hou Mutational spectrum induced by acetaldehyde in the HPRT gene of human T lymphocytes resembles that in the p53 gene of esophageal cancers Carcinogenesis, November 1, 2001; 22(11): 1825 - 1830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Biramijamal, A. Allameh, P. Mirbod, H.-J. Groene, R. Koomagi, and M. Hollstein Unusual Profile and High Prevalence of p53 Mutations in Esophageal Squamous Cell Carcinomas from Northern Iran Cancer Res., April 1, 2001; 61(7): 3119 - 3123. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. Okuda, H. Osugi, K. Morimura, N. Takada, M. Takemura, S. Fukushima, M. Higashino, and H. Kinoshita Detection of p53 Gene Mutations in Human Esophageal Squamous Cell Carcinomas Using a p53 Yeast Functional Assay: Possible Difference in Esophageal Carcinogenesis Between the Young and the Elderly Group Clin. Cancer Res., March 1, 2001; 7(3): 600 - 606. [Abstract] [Full Text]
|
|